New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:08 EDTDNDNDendreon sees Q4 revenue approximately $85.5M, consensus $80.71M
Guidance includes an approximate $3.8M favorable adjustment to the company’s chargebacks reserve due to a change in estimate. On a pro-forma basis, excluding this adjustment, revenue for the quarter is expected to be approximately $81.6M, up 5% on a sequential basis.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2014
07:01 EDTDNDNDendreon: Immune responses enhanced when Provenge given after ADT
Dendreon Corporation announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE is given after androgen deprivation therapy in patients with biochemically-recurrent prostate cancer at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology Congress taking place from April 11-15, 2014 in Stockholm, Sweden.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use